PRN Meeting: September 22, 2021 Jointly provided by the Medical Society of the State of New York, at a Zoom webinar, 7:00 p.m. to 9:00 p.m (EST).

Target Audience:

Physicians, Nurse Practitioners, and Physician Assistants caring for people at risk for, or infected with HIV and/or viral hepatitis.

Course Director: James F. Braun, DO, President, Physicians' Research Network

Moderator: William M. Valenti, MD, Chair, Infectious Diseases Committee of the Medical Society of the State of New York

Guest Speakers and Presentations:

COVID-19 Vaccine Progress and Predicaments

Kristen Marks, MD

Associate Professor of Medicine / Clinical Trials Unit Co-Director
Division of Infectious Disease / Weill Cornell Medical College
New York, NY

Learning Objectives:

At the completion of this educational session, participants will:
1. Know about vaccines under investigation and those available under EUA for prevention of COVID-19 illness.
2. Understand evidence for and against the use of booster doses at this time.
3. Be aware of adverse events of these vaccines and common vaccine management questions.

Anal Cancer Prevention

Stephen E. Goldstone, MD, FACS

Assistant Clinical Professor of Surgery
Icahn School of Medicine at Mount Sinai
New York, NY

Learning Objectives:

At the completion of this educational session, participants will:
1. Be aware of the long-term safety and effectiveness of HPV vaccination.
2. Understand the efficacy of wide field ablation of anal high-grade dysplasia
3. Know whether screening and treating HSIL is reducing anal cancer and who is most at risk based on the most recent data.

Accreditation Statement: This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). The Medical Society of the State of New York (MSSNY) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing Medical Education for physicians.

The Medical Society of the State of New York (MSSNY) designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement:

Dr. Braun (Planner/Course Director) has no relevant financial relationships to disclose. Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose. Dr. Kristen Marks (Presenter) has no relevant financial relationships to disclose. Dr. Marks will support her presentation and clinical recommendations with the best available evidence from the medical literature, and will submit her slides in advance for adequate peer review. Dr. Stephen E. Goldstone (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Investigator for: Merck, Medtronic, and Inovio; Consultant to: Inovio, and THD America; Speaker at: Merck. Dr. Goldstone will support his presentation and clinical recommendations with the best available evidence from the medical literature, and will submit his slides in advance for adequate peer review.

Financial Support:

This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare